Cancer Center Support Grant

总括 项目摘要 普渡大学癌症研究中心(PCCR)是作为NCI基础科学癌症建立的 中心成立于1978年。因此，PCCR的使命侧重于基本的发现--发现是基础 通过它，PCCR促进了创新的癌症解决方案。值得注意的是，PCCR不仅支持基本 发现，还有助于发现应用程序，并在可能的情况下定位发现，以便将其传输到 公有领域。普渡大学在工程、兽医、营养科学、化学、医药等领域的核心优势 化学、药学、结构生物学和生物科学由PCCR合并为功能 研究项目跨学科环境中的基础学科，以推动协作 向创新的癌症解决方案迈进的研究。作为矩阵中心，PCCR的领导力依赖于核心 通过来自普渡大学21个学术部门和7所学院的111名成员，组织 基于三个研究计划的基础设施：新成立的小区身份和信令(CIS) 靶标、结构和药物(TSD)以及药物传递和分子传感(DDMS)。PCCR加快了 通过管理自上次竞争以来重新组织的六个共享资源的发现过程 更新以更好地支持PCCR未来的科学需求：流式细胞术共享资源，计算 基因组学共享资源、生物分子结构共享资源、生命科学质谱学设备 共享资源、生物鉴定共享资源、转基因和基因组编辑设施共享 资源。这些共享资源为研究人员提供了分析细胞的最先进专业知识， 核酸和蛋白质，以确定可用于设计药物的详细分子结构， 评估体内靶点/药物，并开发新的癌症动物模型。这些共享资源服务 被集成到协作发现的PCCR过程中，以生成新的观察结果，从而导致 创新的癌症解决方案。PCCR促进了跨越临床的癌症研究的非凡气息 对自发性恶性肿瘤犬的评估作为药物开发和验证的评估过程 目标和技术，通过干涉测量学和 确定其在创新癌症解决方案的开发中的应用，以及在 基于环境条件下的电离分子进行质谱分析的开创性技术 识别癌症标志物并监测化学反应，以实现连续的自动化合成过程。最后， PCCR保持了癌症中心的基本特征，包括特殊的物理空间， 有效的组织能力，为创新的癌症研究提供基础， 跨学科协作环境，促进以癌症为焦点的基础发现， 普渡大学致力于扩大和加强癌症研究的特殊机构承诺，以及杰出的 中心主任领导力，推动癌症解决方案的开发。

Overall Project Summary The Purdue University Center for Cancer Research (PCCR) was established as an NCI basic science cancer center in 1978. As such, the PCCR's mission focuses on basic discovery - discovery that is the foundation through which the PCCR fosters innovative cancer solutions. Notably, the PCCR not only supports basic discovery but also facilitates discovery application and, where possible, positions discoveries for transfer to the public domain. Purdue core strengths in engineering, veterinary medicine, nutrition science, chemistry, medicinal chemistry, pharmacy, structural biology, and biological sciences, are coalesced by the PCCR into functional Foundational Disciplines within a transdisciplinary environment of Research Programs, to drive collaborative research that moves toward innovative cancer solutions. As a matrix center, PCCR leadership draws on core capabilities through its 111 members from 21 academic departments and 7 colleges across Purdue, to organize an infrastructure based on three Research Programs: Cell Identity and Signaling (CIS), the newly formed Targets, Structures and Drugs (TSD), and Drug Delivery and Molecular Sensing (DDMS). The PCCR expedites the process of discovery by managing six Shared Resources that were reorganized since the last competitive renewal to better support future scientific needs of the PCCR: Flow Cytometry Shared Resource, Computational Genomics Shared Resource, Biomolecular Structure Shared Resource, Life Science Mass Spectrometry Facility Shared Resource, Biological Evaluation Shared Resource, and Transgenic and Genome Editing Facility Shared Resource. These Shared Resources provide researchers access to state-of-the-art expertise to analyze cells, nucleic acids and proteins, to determine detailed molecular structures that can be used to design drugs, to evaluate targets/drugs in vivo, and to develop new animal models of cancer. These Shared Resource services are integrated into the PCCR process of collaborative discovery to generate novel observations that lead to innovative cancer solutions. The PCCR fosters a remarkable breath of cancer research spanning clinical evaluations of dogs with spontaneous malignancies as an evaluative process in drug development and validation of targets and technologies, to probing the fundamentals of molecular motion through interferometry and determining its application to the development of innovative cancer solutions, and to the application of the pioneering technology that is based on ionizing molecules in ambient conditions for mass spectrometry analysis to identify cancer markers and monitor chemical reactions for continuous automated synthesis process. Finally, the PCCR maintains the Essential Characteristics for a cancer center including exceptional Physical Space, effective Organizational Capabilities that provide the foundation for innovative cancer research, a Transdisciplinary Collaborative environment that facilitates fundamental discovery with a Cancer Focus, exceptional Institutional Commitment to expand and enhance cancer research at Purdue, and outstanding Center Director leadership that drives the development of cancer solutions.